HKC has developed the world's first nasal spray vaccine and has been approved for clinical trials!

Guide: This vaccine is nasal, not intramuscular, and the first phase of clinical trials is expected to take 3-4 months to confirm the effectiveness of the vaccine.
is expected to take about a year to complete phase III clinical trials and be officially launched.
the global epidemic continues to spread, and the vaccine research and development race continues.
September 9, the National Key Laboratory for New Infectious Diseases in the Department of Microbiology of the Faculty of Medicine of the University of Hong Kong announced that the new crown vaccine for influenza virus vectors developed with Xiamen University and Beijing Wantay Biometrics has been approved by the State Drug Administration to conduct clinical trials.
understood that this is currently the only clinical trial into the nasal spray new coronary pneumonia vaccine.
vaccine research project is supported by a project of the Ministry of Science and Technology and is one of the five key vaccine technology strategies in the country.
, in collaboration with Xiamen University and Beijing Wantay, has approved clinical trials using the new corona pneumonia vaccine produced by the nasal influenza virus vector, which has been approved by the State Drug Administration for emergency approval.
said the vaccine was a live virus vector vaccine developed in receptor binding areas of the spike protein gene inserted into the retocinded common seasonal influenza virus vector and is now approved for use Clinical trial of the new crown pneumonia candidate vaccine, the only use of nasal spray vaccination method of the vaccine, with safe, easy to use and so on, but also through the simulation of natural infection routes of respiratory viruses, activation of local mucous membrane immune response and systemic immune response and play a highly targeted protective role.
Hong Kong University's National Key Laboratory for New Infectious Diseases, based on long-term influenza research, has recently established a multi-functional influenza virus vector vaccine platform (DelNS1 LAIV), which can quickly construct and express various viral antigens, including coronavirus antigens, using non-toxic influenza virus vaccine vectors to prepare harmless live vaccines.
Guoyong, Professor of Infectious Diseases, Department of Microbiology, Hong Kong University School of Medicine, pointed out that due to the lack of vaccine production facilities in Hong Kong, cooperation with relevant mainland institutions was needed.
, he noted that the vaccine was a nasal spray rather than an intramuscular injection, and that the first phase of clinical trials is expected to take 3-4 months to confirm the vaccine's effectiveness.
is expected to take about a year to complete phase III clinical trials and be officially launched.
Wantay Bio (603392) also announced that the company and Xiamen University, the University of Hong Kong in cooperation with the development of the nasal influenza virus vector new coronary pneumonia vaccine, recently obtained the State Drug Administration clinical trial application acceptance notice and clinical trial approval, agreed to conduct clinical trials, the batch is valid for 12 months.
the requirements of the clinical trial approval, the company has started Phase I clinical research.
At the end of April this year, the Hong Kong Food and Health Bureau announced that hk$111 million had been allocated to its Medical and Health Research Fund to support 26 medical research projects on neo-crown pneumonia at the University of Hong Kong and the Faculty of Medicine of Chinese University of Hong Kong, including research into the spread and spread of the virus, as well as the development of vaccines and new antiviral drugs.
food and health agency has previously said the vaccine will be mass produced and tested on healthy adult volunteers.
.